Mark Weinberger, PhD, MPH, President and CEO of The IMA Group, reflects on the company's 35th anniversary, highlighting how the organization has grown from its roots in medical screenings and psychological evaluations into a national leader with more than 150 locations and a rapidly expanding clinical research network. In a Q&A, Weinberger explains that the company's longevity rests on three pillars: great people, a commitment to quality, and a willingness to adapt and evolve. He notes that IMA's mission is built around helping people at pivotal moments, whether through evaluations for jobs, benefits, or clinical trials.
Weinberger describes IMA as a multifaceted organization that does not fit neatly into a box, serving government agencies, insurers, TPAs, and employers with outsourced medical, psychological, and ancillary evaluations. The company also delivers assessments for public safety programs and supports workers' compensation, disability, and auto liability claims through independent medical exams, medical file reviews, and case management. Additionally, IMA has built a growing clinical research network that leverages its clinic footprint and expertise to connect patients to new treatment opportunities, focusing on therapeutic areas like CNS, sleep, and metabolic disease, as well as GLP-1 studies.
The CEO emphasizes that technology and patient engagement are central to IMA's model, with innovations such as AI tools for trial recruitment, telehealth visits, mobile data capture, and remote monitoring. These tools aim to reduce barriers and improve convenience for patients and sponsors. Looking ahead, Weinberger sees growth in both evaluation and research platforms, including scaling workers' compensation and occupational health evaluations, and piloting new models in hybrid and decentralized trials. He concludes that the company's guiding principles of quality, clinical excellence, scientific rigor, and compassionate humanity will continue to drive its focus on advancing health and earning trust every day.
